Toward Optimum Benefit‐Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles
Karthik Venkatakrishnan(Ono Pharmaceutical (United States)), Ashley Milton(Takeda (United States)), Ajit Suri(Takeda (United States)), M. Lehnert(Merck & Co., Inc., Rahway, NJ, USA (United States)), D DeMuria(Takeda (United States)), Kiyoshi Takeyama(Takeda (Japan)), Xiaofei Zhou(Takeda (United States)), T Takubo(Takeda (Japan)), Neeraj Gupta(Takeda (United States)), C. Burgess(Takeda (United States)), S. Singhvi(Takeda (United States))
Cited by 27
Related Papers
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.
|PubMed|1996|388
Clinical multidrug resistance in cancer: A multifactorial problem
|European Journal of Cancer|1996|178